CAMBRIDGE, Mass.–(Small business WIRE)–Jan 14, 2021–
Amylyx Pharmaceuticals, Inc., a pharmaceutical organization targeted on acquiring new treatment options for amyotrophic lateral sclerosis (ALS), Alzheimer’s Illness and other neurodegenerative health conditions, now declared the appointment of James Frates as Main Fiscal Officer (CFO), productive Jan. 25, 2021. Mr. Frates joins Amylyx next his tenure as CFO at Alkermes, given that 1998.
James Frates, Amylyx Main Financial Officer (Photo: Company Wire)
“We are so fired up for Jim to be a part of us at this significant juncture for Amylyx,” claimed Joshua Cohen, Co-CEO, Chairman and Co-Founder of Amylyx. “Jim’s depth and breadth of working experience as a biopharmaceutical government coupled with his economical acumen and personal mission for bringing promising remedies to individuals with ALS make him a wonderful addition to our management workforce.”
“Jim brings the special combination of experience with rising biopharma businesses concentrated on the central nervous technique, the two as a CFO and a board member, and passion for the individuals we serve,” mentioned Justin Klee, Co-CEO and Co-Founder of Amylyx. “Jim evidently embodies our values and we are thrilled to have him be a part of our mission.”
Frates is an expert chief who served as Alkermes CFO via its expansion from a medical stage corporation to an global industrial and improvement organization with numerous goods, above $1 billion in revenue and around 2000 staff members. Frates served take care of the organization by quite a few acquisitions and financings in the debt, fairness and non-public markets. Prior to Alkermes, Frates labored as an investment banker at Robertson, Stephens & Corporation and Morgan Stanley. Frates currently serves on the Board of Sage Therapeutics, Inc., The Roxbury Latin School and St. Francis Property in Boston. He is a graduate of Harvard College or university and earned an MBA from the Harvard Graduate Faculty of Company Administration.
“Since my cousin Pete Frates was diagnosed with ALS in 2012, and via his remarkable operate with the Ice Bucket Obstacle, I have felt a calling to grow to be additional included in the fight to uncover a lot more effective treatments. I am keen to join Amylyx due to the fact it has designed so significantly progress towards neurodegenerative disorders,” said Frates. “I imagine my encounter can assist the enterprise scale and deliver on its promise of creating a drugs that can assistance hold off neurodegeneration in people. The prospect to support battle ALS means a good offer to me and my loved ones.”
About Amylyx Pharmaceuticals
Amylyx Prescription drugs, Inc. is a pharmaceutical corporation doing the job on establishing a novel therapeutic for amyotrophic lateral sclerosis (ALS), Alzheimer’s condition and other neurodegenerative diseases. For much more facts, check out www.amylyx.com and stick to us on LinkedIn and Twitter.
Search phrase: MASSACHUSETTS UNITED STATES NORTH America
Business Key word: BIOTECHNOLOGY Psychological Overall health OTHER Overall health Health PHARMACEUTICAL
Source: Amylyx Prescribed drugs, Inc.
Copyright Enterprise Wire 2021.
PUB: 01/14/2021 08:00 AM/DISC: 01/14/2021 08:01 AM
Copyright Enterprise Wire 2021.